Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

lousjamsession Jul. 4 at 5:53 AM

$CRVS ....

1 · Reply

tradingjunk321 Jul. 3 at 6:58 PM

$CRVS Like I've been saying for months, next ABVX!

2 · Reply

tradingjunk321 Jul. 3 at 2:09 PM

$CRVS 18 months or less!

0 · Reply

KingKai2020 Jul. 3 at 2:05 PM

$CRVS https://x.com/hothomaswphelps/status/2072921810455118049?s=46

1 · Reply

lousjamsession Jul. 3 at 5:23 AM

$CRVS

2 · Reply

MedicalDoctorInvestor Jul. 3 at 12:13 AM

$CRVS Happy Independence Day weekend friends. And I mean that you you Jelly, Dwsrph25, and Mr King. I hope you have a happy freedom filled 4th with lots of fireworks and good ol America pie. As for me, I caught a flight to DC to celebrate at the national state fair. Going to be great! 🇺🇸

0 · Reply

KingKai2020 Jul. 2 at 6:38 PM

$CRVS up 16% in the past week and up 24% in the last month..... coiling for next week. Keep in mind, given summer trade volumes the shorts will be very exposed to a move up over $20.00

1 · Reply

dwsrph1 Jul. 2 at 6:26 PM

$CRVS Now it’s time for the paint to dry! I bought this stock to pay me high!Now it’s time to get off the hitch! Been waiting a long long time on you batch! It’s high time you get off your ars. Place it high and make us rich. Well hell no one else saying anything. Above is a reverse hex against the Dic’s. Just humor!! 😂😂⚡️

2 · Reply

lousjamsession Jul. 2 at 5:45 AM

$CRVS ....

1 · Reply

MedicalDoctorInvestor Jul. 1 at 5:25 PM

$CRVS

0 · Reply

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Jun 8, 2026, 11:20 AM EDT - 26 days ago

Corvus Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Slides: FY 2026

May 20, 2026, 4:01 PM EDT - 6 weeks ago

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 14, 2026, 1:30 PM EDT - 7 weeks ago

Corvus Pharmaceuticals Transcript: Study update

May 14, 2026, 1:30 PM EDT - 7 weeks ago

Corvus Pharmaceuticals Press release: Study update

May 14, 2026, 1:30 PM EDT - 7 weeks ago

Corvus Pharmaceuticals Slides: Study update

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

SID

2026-05-07T21:26:08.000Z - 2 months ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

May 7, 2026, 4:01 PM EDT - 2 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 2 months ago

Corvus Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Corvus Pharmaceuticals Quarterly report: Q1 2026

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 7:30 AM EDT - 2 months ago

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Apr 21, 2026, 7:30 AM EDT - 2 months ago

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

2026-04-17T08:45:23.000Z - 2 months ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

2026-03-13T12:16:32.000Z - 4 months ago

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

2026-03-13T12:08:45.000Z - 4 months ago

Corvus Pharmaceuticals files automatic mixed securities shelf

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Corvus Pharmaceuticals Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Corvus Pharmaceuticals Earnings release: Q4 2025

2026-03-12T20:05:16.000Z - 4 months ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

Mar 12, 2026, 4:01 PM EDT - 4 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:00 PM EDT - 4 months ago

Corvus Pharmaceuticals Slides: Corporate presentation

Mar 5, 2026, 4:01 PM EST - 4 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Feb 26, 2026, 2:40 PM EST - 4 months ago

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 4 months ago

Corvus Pharmaceuticals Slides: Corporate presentation

Feb 23, 2026, 4:01 PM EST - 4 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-29T11:51:48.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Jan 23, 2026, 5:00 PM EST - 5 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

2026-01-22T17:30:16.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

2026-01-22T13:40:42.000Z - 5 months ago

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

Jan 21, 2026, 10:53 PM EST - 5 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

2026-01-21T13:50:38.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

2026-01-20T21:10:39.000Z - 5 months ago

Corvus Pharmaceuticals announces $150M common stock offering

Jan 20, 2026, 4:01 PM EST - 5 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-01-20T20:30:11.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

Jan 20, 2026, 2:10 PM EST - 5 months ago

What made Corvus stock double on Tuesday and is it sustainable?

2026-01-20T17:35:42.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

2026-01-20T16:05:45.000Z - 5 months ago

Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright

Jan 20, 2026, 8:00 AM EST - 5 months ago

Corvus Pharmaceuticals Transcript: Study result

Jan 20, 2026, 8:00 AM EST - 5 months ago

Corvus Pharmaceuticals Press release: Study result

Jan 20, 2026, 8:00 AM EST - 5 months ago

Corvus Pharmaceuticals Slides: Study result

Jan 16, 2026, 4:01 PM EST - 6 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Nov 10, 2025, 8:30 AM EST - 8 months ago

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:30 PM EST - 8 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Corvus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Corvus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 8 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:00 PM EST - 8 months ago

Corvus Pharmaceuticals Slides: Corporate Presentation

Oct 31, 2025, 7:30 AM EDT - 8 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 9 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Corvus Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Corvus Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Corporate Presentation

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Q1 2025

May 8, 2025, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 4:08 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 27, 2025, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Annual report: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q4 2024

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 11, 2025, 9:20 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Slides: FY 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Press release: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Slides: Study Update

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Sep 10, 2024, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings release: Q2 2024

Aug 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corvus Pharmaceuticals Registration statement: Registration Filing

$Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)$

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Corvus Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Quarterly report: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings release: Q1 2024

May 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

lousjamsession Jul. 4 at 5:53 AM

$CRVS ....

1 · Reply

tradingjunk321 Jul. 3 at 6:58 PM

$CRVS Like I've been saying for months, next ABVX!

2 · Reply

tradingjunk321 Jul. 3 at 2:09 PM

$CRVS 18 months or less!

0 · Reply

KingKai2020 Jul. 3 at 2:05 PM

$CRVS https://x.com/hothomaswphelps/status/2072921810455118049?s=46

1 · Reply

lousjamsession Jul. 3 at 5:23 AM

$CRVS

2 · Reply

MedicalDoctorInvestor Jul. 3 at 12:13 AM

0 · Reply

KingKai2020 Jul. 2 at 6:38 PM

$CRVS up 16% in the past week and up 24% in the last month..... coiling for next week. Keep in mind, given summer trade volumes the shorts will be very exposed to a move up over $20.00

1 · Reply

dwsrph1 Jul. 2 at 6:26 PM

2 · Reply

lousjamsession Jul. 2 at 5:45 AM

$CRVS ....

1 · Reply

MedicalDoctorInvestor Jul. 1 at 5:25 PM

$CRVS

0 · Reply

MedicalDoctorInvestor Jul. 1 at 4:01 PM

$CRVS who’s watching the game tonight!? Who do you think is going to win!? Vote here!

0 · Reply

Buckeye80 Jul. 1 at 2:51 PM

$CRVS has anyone seen the shorts?

2 · Reply

VISIUM Jul. 1 at 1:53 PM

$CRVS good luck to the 18mil short shares that need to be bought back when 100k shares moves the stock $0.50

0 · Reply

Jellysquid1 Jul. 1 at 1:30 PM

$CRVS TODAY Oppenheimer’s Latest Picks One of them For Biotech is CRVS!!!!

0 · Reply

lousjamsession Jul. 1 at 5:20 AM

$CRVS .

2 · Reply

MedicalDoctorInvestor Jun. 30 at 9:36 PM

$CRVS WHY IS THIS GOING UP!! THATS MESSED UP

3 · Reply

Jellysquid1 Jun. 30 at 7:47 PM

$CRVS Let’s close At $15.00 Then Onwards We Go!

0 · Reply

KingKai2020 Jun. 30 at 7:13 PM

$CRVS I am thinking Q3 will be a quarter of accumulation and short covering ahead of Q4 data drops. as a result, the 25k additional trade shares that i bought at $11.50 i am hanging onto. normally i’d book the gains at the close of Q end.

0 · Reply

MedicalDoctorInvestor Jun. 30 at 6:59 PM

$CRVS a joke

0 · Reply

MedicalDoctorInvestor Jun. 30 at 5:00 PM

$CRVS this rally is fading

0 · Reply

ILikeDaStocks Jun. 30 at 4:17 PM

$CRVS I am EXTREMELY confident that...we will look back on the $5, $10, $15, $20, $25 price range and lust like hell!! IF ONLY I owned more! My guess, CRVS will make ABVX look small!! Watch and see...

1 · Reply

Jellysquid1 Jun. 30 at 1:04 PM

$CRVS Shorts Going To Get Burned!🔥

1 · Reply

Market Cap	1.28B
Revenue (ttm)	0.00
Net Income (ttm)	-15.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,318,900
Avg Vol	1,630,166
Day's Range	N/A - N/A
Shares Out	84.09M
Stochastic %K	83%
Beta	0.82
Analysts	Strong Sell
Price Target	$33.33